DS Biopharma, of Dublin, said that recruitment has begun in two separate phase IIb atopic dermatitis (AD) studies with its lead compound, DS107. The study in 300 moderate to severe AD patients is recruiting at sites in the U.S. A topical DS107 phase IIb study in 300 mild to moderate AD patients also is recruiting at sites in Canada and the U.S.